Here’s a year-over-year comparison of Stryker’s first-quarter performance in the last three years:
Q1 2021
Net sales: $4 billion
Spine and neurotechnology sales: $848 million
Total orthopedic sales: $1.5 billion
Knee sales: $412 million
Hip sales: $309 million
Trauma sales: $640 million
Q1 2020
Net sales: $3.6 billion
Spine and neurotechnology sales: $744 million
Total orthopedic sales: $1.2 billion
Knee sales: $432 million
Hip sales: $316 million
Trauma sales: $392 million
Q1 2019
Net sales: $3.5 billion
Spine and neurotechnology sales: $739 million
Total orthopedic sales: $1.3 billion
Knee sales: $439 million
Hip sales: $336 million
Trauma sales: $396 million
More articles on devices:
Why more spine surgeons are looking to invest in ASCs
‘A game-changer’: One spine surgeon’s experience relocating from Brazil to the U.S.
$33M flagship facility opened by 25-physician orthopedic group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.